NCT06258304View on ClinicalTrials.gov

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

November 30, 2027

Conditions
Advanced or Metastatic Solid Tumor Malignancies
Interventions
DRUG

GIGA-564

Administered by intravenous infusion

DRUG

GIGA-564

Administered by intravenous infusion

Trial Locations (1)

20892

RECRUITING

National Cancer Institute, Bethesda

Sponsors

Lead Sponsor

GigaGen, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

GigaGen, Inc.

INDUSTRY